Stock DAWN DAY ONE BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
16.48 USD +10.46% Intraday chart for Day One Biopharmaceuticals, Inc. +7.15% +12.88%
Apr. 29 North American Morning Briefing : Investors Brace -2- DJ
Apr. 24 Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Day One Biopharmaceuticals : Corporate Presentation - April 2024
PU
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
GL
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
AQ
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
GL
Day One Announces Two New Appointments to Board of Directors
GL
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
GL
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
AQ
Day One Biopharmaceuticals : Change in Certifying Accountants - Form 8-K
PU
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
GL
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
GL
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
AQ
Day One Biopharmaceuticals : Corporate Presentation - October 2023
PU
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
GL
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
AQ
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
GL
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
GL
Sprint Bioscience licenses the VADA (VRK1) program to Day One Biopharmaceuticals
AQ
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
AQ
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DAWN Stock
  4. News Day One Biopharmaceuticals, Inc.
  5. Press Releases